Literature DB >> 7097553

The serum kinetics of bovine testicular hyaluronidase in dogs, rats and humans.

R A Wolf, L Y Chaung, D O'Hara, T W Smith, J E Muller.   

Abstract

There is experimental and clinical evidence that i.v. injection of bovine testicular hyaluronidase (BTH) reduces the extent of necrosis during myocardial infarction. The fate of i.v. administered BTH has not been described. In this study, serum kinetics of BTH enzyme activity in dogs, rats and humans were determined. Tissue distribution of BTH was determined with an 125I-labeled preparation of purified BTH. Serum BTH activity initially decreased exponentially with half-life 2.0 +/- 0.1 min in dogs with coronary artery occlusion (n = 8; 500 U of BTH/kg); 3.2 min in humans with acute myocardial infarction (n = 2; 500 U of BTH/kg); and 3.2 +/- 0.3 min in rats (n = 5; 5,000 U of BTH/kg). In dogs BTH disappearance showed two distinct phases. After injection of high dose BTH (5,000 U of BTH/kg), during the first 7 min serum half-life of BTH was 2.1 +/- 0.2 min (n = 8), but increased to 9.4 min in later serum samples. After the injection of 125I-labeled BTH into the rat, protein-bound 125I disappeared from serum with a half-life (3.4 min) that is similar to the serum half-life of BTH enzyme activity (3.2 min). Twenty minutes after injection of 125I-labeled BTH, 30% of the label was recovered in the liver. It is concluded that BTH activity has a short serum half-life of less than 10 min in dogs, rats and humans. In the rat model, the disappearance of serum BTH activity results from physical removal of circulating BTH molecules rather than serum inhibition or inactivation of BTH enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7097553

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Delay of development of transmural irreversible ischaemic injury in canine myocardium.

Authors:  P K Kirchner; P Alpers; M Hofmann; M Gottwik; J Schaper
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

2.  A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers.

Authors:  Marie A Printz; Samuel S Dychter; Emanuel P DeNoia; Rena Harrigan; Barry J Sugarman; Monica Zepeda; Jennifer Souratha; David W Kang; Daniel C Maneval
Journal:  Curr Ther Res Clin Exp       Date:  2020-08-19

3.  The recovery time course of the endothelial cell glycocalyx in vivo and its implications in vitro.

Authors:  Daniel R Potter; John Jiang; Edward R Damiano
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

4.  Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.

Authors:  Salima Hamizi; Gilles Freyer; Naoual Bakrin; Emilie Henin; Amina Mohtaram; Olivia Le Saux; Claire Falandry
Journal:  Onco Targets Ther       Date:  2013-02-14       Impact factor: 4.147

5.  Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer.

Authors:  David W Kang; Beate Bittner; Barry J Sugarman; Monica L Zepeda; Marie A Printz
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.